Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma-A 3-D In Vitro Study

International Journal of Molecular Science 2022 June 30 [Link] Claudia Baron, Marie Buchholz, Britta Majchrzak-Stiller, Ilka Peters, Daniel Fein, Thomas Müller, Waldemar Uhl, Philipp Höhn, Johanna Strotmann, Chris Braumann Abstract Malignant peritoneal mesothelioma is a rare tumor entity. Although cytoreductive surgery and hyperthermic intraperitoneal chemotherapy have increased overall survival, its prognosis remains poor. Established chemotherapeutics…

Read More

Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

Langenbeck’s Archives of Surgery 2022 June 23 [Link] Miklos Acs, Michael Gerken, Ivana Gajic, Max Mayr, Jozef Zustin, Pompiliu Piso Abstract Purpose: This single-center study evaluated cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for diffuse malignant peritoneal mesothelioma (DMPM). Methods: Prospectively collected data from a single institution data registry was retrospectively investigated. Eighty-four…

Read More

Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Outcomes and Survival From an Australian Centre

Anticancer Research 2022 June [Link] Raphael Shamavonian, Ernest Cheng, Josh B Karpes, Shoma Barat, Nima Ahmadi, David L Morris Abstract Background/aim: The aim of the study was to determine outcomes and overall survival (OS) in patients undergoing cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for malignant peritoneal mesothelioma (MPM). Patients and methods: This was…

Read More

A Canadian single-centre experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for abdominal malignancies

Canadian Journal of Surgery 2022 May 17 [Link] Rami Nassabein, Rami Younan, Rasmy Loungarath, Frederic Mercier, Francois Dagbert, Francine Aubin, Jean Pierre Ayoub, Mustapha Tehfé Abstract Background: Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) has recently shown promise for the treatment of patients with various types of peritoneal carcinomatosis (PC). However, it is…

Read More

Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis: A 30-year Institutional Experience

Annals of Surgical Oncology 2022 March 14 [Link] Cristian D Valenzuela, Edward A Levine, Christopher W Mangieri, Rohin Gawdi, Omeed Moaven, Gregory Russell, Megan E Lundy, Kathleen C Perry, Konstantinos I Votanopoulos, Perry Shen Abstract Background: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) improves survival in abdominal cancer patients with metastatic disease limited to the…

Read More

Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study

Annals of Surgical Oncology 2021 October 28 [Link] Vahan Kepenekian, Julien Péron, Benoit You, Isabelle Bonnefoy, Laurent Villeneuve, Mohammad Alyami, Naoual Bakrin, Pascal Rousset, Nazim Benzerdjeb, Olivier Glehen Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive primary peritoneal neoplasia. At diagnosis, few patients are eligible for a recommended cytoreductive surgery (CRS) and hyperthermic…

Read More

Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases

Frontiers in Oncology 2021 June 18 [Link] Louis Gros, Petr Szturz, Antonella Diciolla, Volker Kirchner, Solange Peters, Niklaus Schaefer, Martin Hubner, Antonia Digklia Abstract Mesothelioma is a malignancy of serosal membranes. Parietal pleura is the most common site, with peritoneum being the second most frequent location. Malignant peritoneal mesothelioma (MPM) is a rare and aggressive…

Read More

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in pediatric patients with peritoneal mesothelioma: a single institution experience and long term follow up

International Journal of Hyperthermia 2021 [Link] Parisa Malekzadeh, Meghan Good, Marybeth S Hughes Abstract Introduction: Malignant peritoneal mesothelioma (MPM) is a lethal cancer, with approximately 2% of diagnoses occurring in patients less than 40 years of age. The purpose of this study is to report the only long-term follow up and survival of pediatric patients…

Read More

Feasibility and outcomes of cytoreductive surgery and HIPEC for peritoneal surface malignancies in low- and middle-income countries: a single-center experience of 232 cases

World Journal of Surgical Oncology 2021 June 5 [Link] Suryanarayana Deo, Mukurdipi Ray, Babul Bansal, Sandeep Bhoriwal, Sushma Bhatnagar, Rakesh Garg, Nishkarsh Gupta, Atul Sharma, Lalit Kumar, Sanjay Thulkar, Ekta Dhamija, Sandeep Mathur, Prasenjit Das Abstract Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has recently emerged as a viable management option for peritoneal…

Read More